ライフサイエンスコーパス: respiratory tract

1 eutic potential as a antispasmodic agent for respiratory tract.

2 cts ciliated epithelial cells in the chicken respiratory tract.

3 neal fluid at a higher concentration than in respiratory tract.

4 3 were produced and secreted along the upper respiratory tract.

5 9 can present as a mild illness of the upper respiratory tract.

6 ressed in a subset of secretory cells in the respiratory tract.

7 ed by asymptomatic colonization of the upper respiratory tract.

8 event secondary NTHI-induced diseases of the respiratory tract.

9 les collected, 228 (97%) were from the upper respiratory tract.

10 r, its replication is restricted only to the respiratory tract.

11 g sweeping mucus, dirt and debris out of the respiratory tract.

12 n resolution of RSV-A infection in the upper respiratory tract.

13 e intrinsic conditions within the host upper respiratory tract.

14 ctions by IAV may reach sites other than the respiratory tract.

15 rly colonization and infection of the bovine respiratory tract.

16 DNA, such as those from the skin, tissue and respiratory tract.

17 etworks, such as the vascular network or the respiratory tract.

18 ogen to prevent NTHI-induced diseases of the respiratory tract.

19 source is optimized for its position in the respiratory tract.

20 e system at two major barriers: the skin and respiratory tract.

21 e, bacterial colonizers and pathogens in the respiratory tract.

22 virus targets epithelial cells in the upper respiratory tract.

23 n the extracellular environment of the upper respiratory tract.

24 ve virus replication in tissues of the upper respiratory tract.

25 when SARS-CoV-2 is undetectable in the upper respiratory tract.

26 the pathogenesis of S. aureus to include the respiratory tract.

27 and propagation, do not adequately model the respiratory tract.

28 immune responses to viral infections in the respiratory tract.

29 acterium that frequently colonises the upper respiratory tract.

30 elop lung inflammation and remodeling of the respiratory tract.

31 iple diseases throughout the upper and lower respiratory tracts.

32 -CoV-2 infection in both the upper and lower respiratory tracts.

33 onsils are the lymph nodes serving the upper respiratory tract, acting as both induction and effector

34 beta-Defensins protect the respiratory tract against the myriad of microbial pathog

35 y understood, a transition occurs within the respiratory tract and a sudden explosive proliferation o

36 eumoniae is a natural colonizer of the human respiratory tract and an opportunistic pathogen.

37 a wide range of anatomic sites including the respiratory tract and bloodstream.

38 tly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread to un

39 pergillosis when spores are inhaled into the respiratory tract and invade airway or lung tissue.

40 can be involved in AAV, the upper and lower respiratory tract and kidneys are most commonly and seve

41 mall enough to enter the human brain via the respiratory tract and olfactory bulbs.

42 exclusively in human samples and mostly from respiratory tract and oro-pharyngeal sites, where Redond

43 Paramyxoviruses infect the respiratory tract and the central nervous system (CNS) a

44 e of influenza infection occurs in the upper respiratory tract and the trachea, but little is known a

45 has a tissue tropism for the upper and lower respiratory tracts and a cellular tropism for type 1 and

46 ta and mucous barriers (gastrointestinal and respiratory tract) and their importance in the onset and

47 current pandemic, predominantly affects the respiratory tract, and a growing number of publications

48 thology is pronounced in the upper and lower respiratory tract, and disease signs and endpoints inclu

49 st-environment interfaces, such as the skin, respiratory tract, and oral/gastrointestinal mucosa.

50 n various tissues, including the thyroid and respiratory tract, and plays a crucial role in processes

51 us (hRV) is frequently detected in the upper respiratory tract, and symptomatic infection is associat

52 well in epithelial cells of the swine upper respiratory tract, and these viruses were shown to infec

53 Viral infections of the lower respiratory tract are a leading cause of mortality.

54 nfluenza-specific T cells resident along the respiratory tract are highly effective at providing pote

55 Recognizing the respiratory tract as a dynamic and complex ecosystem has

56 infections, this is beneficial in the upper respiratory tract because it disrupts colonization resis

57 nt and eliminate bacterial infections of the respiratory tract, but it is unknown whether sphingosine

58 ed oligosaccharide receptors to colonize the respiratory tract, but the contribution of the latter is

59 mechanism of harmful irritant effects in the respiratory tract caused by accidental exposure to a hig

60 gh (pertussis), a bacterial infection of the respiratory tract caused by the bacterium Bordetella per

61 7 displayed robust replication in the ferret respiratory tract, causing slight fever and moderate wei

62 he ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-symptom

63 HA activation, in vitro replication in human respiratory tract cells, and in vivo mammalian pathogeni

64 sed for their capacity to replicate in human respiratory tract cells, and to cause disease and transm

65 ctices during UC encounters, with a focus on respiratory tract conditions.

66 Rationale: The respiratory tract constitutes an elaborate line of defen

67 Patients with positive respiratory tract cultures are clinically different from

68 Patients with positive respiratory tract cultures are clinically different from

69 velopment of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to

70 gens and unwanted surface materials from the respiratory tract, depends on the coordinated function o

71 -20 mum), along with estimated exposures and respiratory-tract deposition.

72 A multivariate risk factor analysis of lower-respiratory tract disease (LRTD) identified 2 conditions

73 s (RSV) is the leading cause of infant lower respiratory tract disease and hospitalization worldwide.

74 l virus (RSV) is a top cause of severe lower respiratory tract disease and mortality in infants and t

75 occal carriage did not impact rates of lower respiratory tract disease for these 3 viruses.

76 ) are positive-strand RNA viruses that cause respiratory tract disease in children and adults.

77 us (RSV) is the leading viral cause of lower respiratory tract disease in infants and children worldw

78 s with AERD have more severe upper and lower respiratory tract disease than do aspirin-tolerant patie

79 ases (lung cancer, stroke, and chronic lower respiratory tract diseases) and examined the simultaneou

80 he dynamics of bacterial colonization of the respiratory tract during viral upper respiratory tract i

81 o kidney cells, human fibroblasts, and human respiratory tract epithelial cells.

82 biofilms and resist oxidative stress in the respiratory tract facilitates systemic dissemination and

83 n dosimetry due to particles decaying in the respiratory tract from environmental radioactive exposur

84 ion of active virus replication in the upper respiratory tract has implications for the containment o

85 The human respiratory tract hosts a diverse community of cocircula

86 Within the human respiratory tract (HRT), virus diffuses through the peri

87 had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses

88 syncytial virus (RSV) is a leading cause of respiratory tract illness in young children and a major

89 manifested as severe, life-threatening lower respiratory tract illness with high rates of pneumonia,

90 ading global cause of severe pediatric acute respiratory tract illness, and a vaccine is needed.

91 se 2019 (COVID-19), a recently emerged lower respiratory tract illness, has quickly become a pandemic

92 igns; signal was primarily visualized in the respiratory tract in animals with acute-onset terminal d

93 s 2 (SARS-CoV-2) receptor, is reduced in the respiratory tract in children.

94 V-1 challenge virus replication in the upper respiratory tract in fully protected horses.

95 do not increase aerosol generation from the respiratory tract in healthy human participants with no

96 rasuis is a commensal bacterium of the upper respiratory tract in pigs and also the causative agent o

97 of viral replication in the upper and lower respiratory tracts in nonhuman primates(11-13).

98 dverse events in all groups were viral upper respiratory tract infection (14-16%) and worsening asthm

99 The most common adverse events were upper respiratory tract infection (36 [10%] patients) and head

100 rse events included fatigue (62%), and upper respiratory tract infection (42%), infusion reactions (4

101 revalent ARI syndromes included: viral upper respiratory tract infection (47%), pharyngitis (18%), an

102 , headache (57 [15%] vs 46 [12%]), and upper respiratory tract infection (51 [13%] vs 30 [8%]).

103 , 2.75; 95% CI, 2.03 to 3.73), current upper respiratory tract infection (adjusted odds ratio, 1.35;

104 ong the most important causes of acute lower respiratory tract infection (ALRI) in young children.

105 s to identify biomarkers of severe RSV acute respiratory tract infection (ARTI) in infants.

106 cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).

107 nical trial of the FDA-cleared Unyvero lower respiratory tract infection (LRTI) application (Curetis)

108 ith respiratory failure (RF) and fatal lower respiratory tract infection (LRTI) in premature children

109 evious pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significantly ass

110 nfirmed hospitalizations or outpatient lower respiratory tract infection (LRTI).

111 I), urinary tract infection (UTI), and lower respiratory tract infection (LRTI).

112 Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were considered t

113 ost common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [

114 syncytial virus (RSV) is a leading cause of respiratory tract infection (RTI) in young children.

115 Consultations for respiratory tract infection (RTI), skin or urinary tract

116 t paediatric diarrhoea and adult acute upper respiratory tract infection (URTI), which were presented

117 There are no antivirals to treat viral upper respiratory tract infection (URTI).

118 (QoL) assessments and the incidence of upper respiratory tract infection (URTI).

119 al virus (RSV) is the leading cause of lower respiratory tract infection among infants and young chil

120 yncytial virus is the leading cause of lower respiratory tract infection among infants.

121 ate with the incidence and severity of acute respiratory tract infection and childhood asthma develop

122 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess s

123 g viral pathogen associated with acute lower respiratory tract infection and hospitalization in child

124 It is a major cause of acute lower respiratory tract infection and is associated with signi

125 ic patterns of AWaRe antibiotic use in lower respiratory tract infection and neonatal sepsis were obs

126 anisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE

127 er fashion as regards risk factors for lower respiratory tract infection and there is evidence that t

128 Early-life wheezing-associated respiratory tract infection by rhinovirus (RV) is a risk

129 Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coro

130 Lower respiratory tract infection contributed to 174 (57%) of

131 Mortality from lower respiratory tract infection fell as cognitive ability in

132 ween neonatal interferon responses and lower respiratory tract infection history during infancy, whee

133 ] women), clinical presentation was an upper respiratory tract infection in 12 (67%), and viral shedd

134 d, although hMPV is a leading cause of lower respiratory tract infection in children.

135 rus (hMPV) is a leading cause of viral lower respiratory tract infection in children.

136 b for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had b

137 ion is a leading cause of severe acute lower respiratory tract infection in infants and children worl

138 virus (RSV) is a significant cause of lower respiratory tract infection in infants and elderly.

139 l virus (RSV) is the leading cause of severe respiratory tract infection in infants and young childre

140 RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of

141 irus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exist

142 (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most se

143 irmed COVID-19 adults with symptoms of lower respiratory tract infection in the emergency department

144 was medically attended RSV-associated lower respiratory tract infection through 150 days after admin

145 was hospitalization for RSV-associated lower respiratory tract infection through 150 days after admin

146 RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and t

147 RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine grou

148 e of medically attended RSV-associated lower respiratory tract infection was 70.1% lower (95% confide

149 of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower (95% CI, 51.

150 Upper respiratory tract infection was the most frequent treatm

151 for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine

152 had been admitted to a hospital with a lower respiratory tract infection with a pneumonia index score

153 ponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0

154 which were nasopharyngitis, influenza, upper respiratory tract infection, and headache.

155 Dementia increases the risk of lower respiratory tract infection, but it is unclear whether r

156 st frequently reported on-treatment AEs were respiratory tract infection, headache, bronchitis, and a

157 of the respiratory tract during viral upper respiratory tract infection, in addition to the relation

158 DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased app

159 atracheal routes to cause an upper and lower respiratory tract infection, respectively.

160 ted with intravenous ceftriaxone for a lower respiratory tract infection, thereby supporting continue

161 ibing rates when diagnostics suggested viral respiratory tract infection, without a higher rate for r

162 ibing rates when diagnostics suggested viral respiratory tract infection, without a higher rate for r

163 clinical presentation was frequently a mild respiratory tract infection.

164 dverse events were nasopharyngitis and upper respiratory tract infection.

165 ommon adverse events were headache and upper respiratory tract infection.

166 ERS) coronavirus causes a highly fatal lower-respiratory tract infection.

167 re infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]), and

168 dren worldwide, commonly through acute lower respiratory tract infections (ALRI).

169 Acute respiratory tract infections (ARI) constitute a substant

170 t support use of systemic steroids for acute respiratory tract infections (ARTIs), but such practice

171 Lower respiratory tract infections (LRTIs) are a leading cause

172 Childhood lower respiratory tract infections (LRTIs) cause substantial m

173 In contrast, non-CAAP lower respiratory tract infections (NA-LRI) are generally not

174 In contrast, non-CAAP lower respiratory tract infections (NA-LRIs) are generally not

175 The clinical signs and symptoms of acute respiratory tract infections (RTIs) are not pathogen spe

176 s in the prospective cohort, 21 distinct BoV respiratory tract infections (RTIs) were observed by 1 y

177 ct microbiota are related to pathogenesis of respiratory tract infections (RTIs).

178 in uncomplicated urinary and upper and lower respiratory tract infections (RTIs).

179 Upper respiratory tract infections (URTIs) are important trigg

180 Chinese primary care to children with upper respiratory tract infections (URTIs), we developed an in

181 ewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than p

182 um antibiotics and those admitted with lower respiratory tract infections and skin and soft tissue in

183 Respiratory tract infections are often viral and but are

184 Although non-CAAP lower respiratory tract infections are usually not considered

185 ntification of the causative agents of lower respiratory tract infections can promote better patient

186 inflammation is a critical feature of lower respiratory tract infections caused by viruses such as r

187 Coronaviruses cause respiratory tract infections in humans and outbreaks of

188 nts.IMPORTANCE Influenza viruses cause upper respiratory tract infections in humans.

189 (RSV) is a major cause of severe acute lower respiratory tract infections in infants.

190 yncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, curren

191 e of the significant pathogens causing acute respiratory tract infections in young children worldwide

192 rus of the Parvoviridae family, causes acute respiratory tract infections in young children.

193 risk of respiratory morbidity from recurrent respiratory tract infections including those from respir

194 the performance of BN in infants with acute respiratory tract infections with different degrees of d

195 confirmed RSV ARTI (includes upper and lower respiratory tract infections), 500 without and 50 with c

196 5%] had bronchitis, 34 [12%] had viral upper respiratory tract infections), cough (34 [12%]), and dia

197 tobacco smoke, controller medication, upper respiratory tract infections, and seasonality.

198 me comprising a range of potentially serious respiratory tract infections, contributes to mortality i

199 Lower respiratory tract infections, including hospital-acquire

200 body deficiencies (PADs) experience frequent respiratory tract infections, leading to chronic pulmona

201 eated with intravenous ceftriaxone for lower respiratory tract infections, oral ribaxamase reduced th

202 breakthrough in the field of multimicrobial respiratory tract infections, wherein control of inflamm

203 method for detection of pathogens from lower respiratory tract infections.

204 ult patients with bronchiectasis and chronic respiratory tract infections.

205 piratory syncytial virus (RSV)-induced lower respiratory tract infections.

206 in patients with bronchiectasis and chronic respiratory tract infections.

207 actor for the development of recurrent upper respiratory tract infections.

208 cept were injection-site reactions and upper respiratory tract infections.

209 nriched in clinical isolates associated with respiratory tract infections.

210 t common indications were skin disorders and respiratory tract infections.

211 ts frequently present to doctors with severe respiratory tract infections.

212 enza virus (PIV) is a leading cause of lower respiratory tract infections.

213 fections (54 [19%] of 278 patients had upper respiratory tract infections; 42 [15%] had bronchitis, 3

214 en and is the leading cause of serious lower-respiratory-tract infections in young children.

215 respiratory tract infectious disease, lower respiratory tract infectious disease (LRTID), or acute r

216 g seasonal changes, from patients with upper respiratory tract infectious disease, lower respiratory

217 is unknown from which anatomical site of the respiratory tract influenza A virus transmission occurs.

218 e for rapid bacterial dissemination from the respiratory tract into the blood.

219 While the classical form with renal and respiratory tract involvement is mainly seen, a limited

220 The upper respiratory tract is the primary site for GAS colonizati

221 pneumoniae, a normal commensal of the upper respiratory tract, is a major public health concern, res

222 esistant pneumococci isolated from the lower respiratory tract (LRT) of adults.

223 The Unyvero lower respiratory tract (LRT) panel (Curetis, Holzgerlingen, G

224 ), but the concordance between URT and lower respiratory tract (LRT) RV detection is not well charact

225 gs affect bacterial replication in the lower respiratory tract (LRT).

226 Microbial exposures in respiratory tract may contribute to neutrophil mobilizat

227 es in the oropharynx, variation in the upper respiratory tract microbiome may create conditions that

228 sess the concordance between upper and lower respiratory tract microbiota during LRTIs and the use of

229 robiota can serve as a valid proxy for lower respiratory tract microbiota in childhood LRTIs, that cl

230 ize-segregated chemical composition, a human respiratory tract model, and kinetic modeling, we quanti

231 ection and their fitness in an ex vivo upper respiratory tract model.

232 replication was observed mainly in the upper respiratory tract (nasal turbinates) but also in the low

233 -CoV-2) shedding was observed from the upper respiratory tract of a female immunocompromised individu

234 ioactive aerosols was then registered to the respiratory tract of an image-based whole-body adult mal

235 e mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase

236 rating that they are expelled from the upper respiratory tract of ferrets rather than from trachea or

237 of particles and droplets generated from the respiratory tract of humans exposed to various oxygen de

238 zing S. pneumoniae colonization of the upper respiratory tract of infant mice.

239 act (nasal turbinates) but also in the lower respiratory tract of infected mice, with a peak at 4 day

240 not replicate to high titers throughout the respiratory tract of mice and ferrets.IMPORTANCE Bats ar

241 affect colonization or initial growth in the respiratory tract of mice, its natural host, but did inc

242 a limited effect on SARS-CoV-2 in the upper respiratory tract of this individual.

243 transgene was specifically expressed in the respiratory tract of transgenic mice upon induction by b

244 tiated human airway epithelial cultures, and respiratory tracts of cotton rats.

245 was highly attenuated in the upper and lower respiratory tracts of cotton rats.

246 thin the upper (nasal) and lower (pulmonary) respiratory tracts of human donors using a diverse panel

247 immunobiotic Lactobacillus plantarum to the respiratory tracts of PVM-infected mice promoted surviva

248 at the tissue tropisms (i.e., in swine upper respiratory tracts) of avian IAVs affect their spillover

249 h decreasing expression throughout the lower respiratory tract, paralleled by a striking gradient of

250 , due to their efficacy on relaxation of the respiratory tract, posses a therapeutic potential as a a

251 Influenza virus infects the respiratory tract, providing a specific environmental ni

252 o promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-

253 d viscoelastic films, including those in the respiratory tract responsible for aerosol production fro

254 ly, the dissociation between upper and lower respiratory tract results underscores the need for close

255 ia were (a) positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain

256 by day 30, and is highest in feces and lower respiratory tract samples.

257 ther human coronaviruses targeting the lower respiratory tract - severe acute respiratory syndrome co

258 licate P. aeruginosa isolates from blood and respiratory tract sources were recovered from patients a

259 e preanalytical stage, collecting the proper respiratory tract specimen at the right time from the ri

260 PP) for identification of pathogens in lower respiratory tract specimens (n = 200) from emergency dep

261 microbial resistance marker genes from lower respiratory tract specimens (sputum and bronchoalveolar

262 6 HCT recipients with BoV detected in lower respiratory tract specimens [incidence rate of 0.4% (9/2

263 Classical P1-2 was more frequent in lower respiratory tract specimens and had longer p1 trinucleot

264 was quantified in available upper- and lower-respiratory tract specimens as well as fecal and blood s

265 rmalities, and Legionella detection in lower respiratory tract specimens by culture and/or real-time

266 coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare

267 Respiratory viruses in upper- and/or lower-respiratory tract specimens were tested using multiplex

268 of HCT recipients with BoV detected in lower respiratory tract specimens.

269 rome coronavirus 2 (SARS-CoV-2) RNA in upper respiratory tract specimens.

270 assessed using 483 remnant upper- and lower-respiratory-tract specimens previously analyzed by stand

271 SARS-CoV-2 in a variety of upper- and lower-respiratory-tract specimens.

272 ns (blood, cerebrospinal fluid, lung tissue, respiratory tract swabs, and rectal swabs) for >100 real

273 Additionally, an augmentation of upper respiratory tract symptom scores and LRTS scores occurre

274 imary outcome for both trials compared lower respiratory tract symptoms (LRTSs) between study groups

275 Mild upper respiratory tract symptoms and/or fever occurred in vacc

276 tionally develop significant upper and lower respiratory tract symptoms on ingestion of cycloxgenase-

277 VID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential

278 se to RV16 at day 3 is associated with upper respiratory tract symptoms.

279 cell responses, whereas Aer induced powerful respiratory tract T cell responses but a low titer of Ab

280 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 2019(1,2).

281 sses models for mimicking blood vessels, the respiratory tract, the gastrointestinal tract, renal tub

282 indicate that virus replication in the upper respiratory tract, the nasal respiratory epithelium in p

283 n the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques t

284 with sporadic virus dissemination beyond the respiratory tract, to severe disease with fatal outcome.

285 effects of influenza infection on the upper respiratory tract (URT) microbiome are largely unknown.

286 with respiratory viruses (RVs) in the upper respiratory tract (URT), but the concordance between URT

287 5% of the isolates and was more common among respiratory tract versus bloodstream specimens.

288 While all IBV strains infect the chicken respiratory tract via the ciliated epithelial layer of t

289 infection (OR = 7.51; 95% CI = 4.37-12.91), respiratory tract viral infection (OR = 7.75; 95% CI = 1

290 in the context of prior or concurrent upper respiratory tract viral infection, this bacterium common

291 cycle thresholds, suggestive of higher upper respiratory tract viral loads, but not with increased di

292 Virus shedding from the upper respiratory tract was not reduced by remdesivir treatmen

293 Here, as SARS-CoV-2 primarily infects the respiratory tract, we developed a lung organoid model us

294 icipants, the levels of ADAMTS4 in the lower respiratory tract were associated with the severity of i

295 dy, host-pathogen interactions in the bovine respiratory tract were mimicked using a novel differenti

296 Infections of the respiratory tract were the leading indication for antibi

297 atically, and the more distal regions of the respiratory tract where NTHI-induced diseases occur.

298 tely reflect etiologic agents from the lower respiratory tract where sputum specimens are considered

299 ted in robust virus replication in the upper respiratory tract, whereas mice deficient for MHC-II wer

300 The amount of aerosol generation from the respiratory tract with these various oxygen modalities i